On Friday, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was -8.92% drop from the session before settling in for the closing price of $120.82. A 52-week range for JAZZ has been $99.06 – $148.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 13.88% over the last five years. When this article was written, the company’s average yearly earnings per share was at 11.51%. With a float of $57.97 million, this company’s outstanding shares have now reached $60.63 million.
The firm has a total of 2800 workers. Let’s measure their productivity. In terms of profitability, gross margin is 84.57%, operating margin of 17.86%, and the pretax margin is 11.56%.
Jazz Pharmaceuticals plc (JAZZ) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Jazz Pharmaceuticals plc stocks. The insider ownership of Jazz Pharmaceuticals plc is 4.54%, while institutional ownership is 97.57%. The most recent insider transaction that took place on Apr 01 ’25, was worth 185,625. In this transaction Chairman & CEO of this company sold 1,500 shares at a rate of $123.75, taking the stock ownership to the 440,307 shares. Before that another transaction happened on Apr 01 ’25, when Company’s Officer proposed sale 2,000 for $125.31, making the entire transaction worth $250,625.
Jazz Pharmaceuticals plc (JAZZ) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 5.78 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 11.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.15% during the next five years compared to -1.00% drop over the previous five years of trading.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Trading Performance Indicators
You can see what Jazz Pharmaceuticals plc (JAZZ) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.64. Likewise, its price to free cash flow for the trailing twelve months is 4.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 8.70, a number that is poised to hit 4.78 in the next quarter and is forecasted to reach 22.87 in one year’s time.
Technical Analysis of Jazz Pharmaceuticals plc (JAZZ)
Analysing the last 5-days average volume posted by the [Jazz Pharmaceuticals plc, JAZZ], we can find that recorded value of 1.49 million was better than the volume posted last year of 0.96 million. As of the previous 9 days, the stock’s Stochastic %D was 10.62%. Additionally, its Average True Range was 4.98.
During the past 100 days, Jazz Pharmaceuticals plc’s (JAZZ) raw stochastic average was set at 0.73%, which indicates a significant decrease from 0.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.09% in the past 14 days, which was higher than the 32.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $132.03, while its 200-day Moving Average is $118.66. Now, the first resistance to watch is $114.85. This is followed by the second major resistance level at $119.66. The third major resistance level sits at $122.20. If the price goes on to break the first support level at $107.50, it is likely to go to the next support level at $104.95. Should the price break the second support level, the third support level stands at $100.14.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Key Stats
There are 60,732K outstanding shares of the company, which has a market capitalization of 6.68 billion. As of now, sales total 4,069 M while income totals 560,120 K. Its latest quarter income was 1,088 M while its last quarter net income were 191,120 K.
